Oncimmune Holdings PLC Director/PDMR Shareholding (6994B)
06 June 2023 - 1:02AM
UK Regulatory
TIDMONC
RNS Number : 6994B
Oncimmune Holdings PLC
05 June 2023
5 June 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Director/PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, has been notified that Dr Adam Mark Hill,
PDMR and Chief Executive Officer, today purchased 48,370 ordinary
shares of GBP0.01 each in the Company ("Ordinary Shares") at a
price of GBP0.206533 per share.
Following this transaction, Dr Hill has a total interest in the
Company of 122,242 Ordinary Shares, representing approximately 0.17
per cent. of the Company's issued share capital of 74,142,147.
In addition, Dr Hill holds options over a total of 3,615,862
Ordinary Shares, representing approximately 4.88 per cent. of the
Company's issued share capital.
This announcement, including the notification below, is made in
accordance with the requirements of Article 19 of the UK Market
Abuse Regulation.
Notification and public disclosure of transactions by person
discharging managerial responsibilities and persons closely
associated with them:
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Dr Adam Mark Hill
------------------------------------- --------------------------------------
Reason for the notification
2
-----------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------------- --------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------------- --------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Oncimmune Holdings plc
------------------------------------- --------------------------------------
b) LEI 213800HCYIWT6YPI1I02
------------------------------------- --------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description of the Ordinary Shares of GBP0.01 each
financial instrument,
type of instrument
Identification code ISIN: GB00BYQ94H38
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------------- --------------------------------------
c) Price(s) and volume(s)
------------------- --------------
Price(s) Volume(s)
------------------- --------------
GBP0.206533 48,370
-------------------------------------------------------------- --------------
d) Aggregated information N/A - single transaction
- Aggregated volume
- Price
e) Date of the transaction 5 June 2023
------------------------------------- --------------------------------------
f) Place of the transaction London Stock Exchange, AIMX
------------------------------------- --------------------------------------
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. The ImmunoINSIGHTS service
business leverages Oncimmune's technology platform and
methodologies across multiple diseases, to offer life-science
organizations actionable insights for therapies across the
development and product lifecycle. Our core immune-profiling
technology is underpinned by our library of over eight thousand
immunogenic proteins, one of the largest of its kind. This helps
identify trial participants and patients into clinically relevant
subgroups, enabling development of targeted and more effective
treatments.
Oncimmune's ImmunoINSIGHTS service business is based at the
Company's discovery research centre in Dortmund, Germany. The
business platform enables life science organizations to optimize
drug development and delivery, leading to more effectively targeted
and safer treatments for patients.
The ImmunoINSIGHTS development team is based in the US and
Europe and Oncimmune is seeking to replicate the Dortmund facility
in the US in the medium term.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHZELFBXQLEBBV
(END) Dow Jones Newswires
June 05, 2023 11:02 ET (15:02 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024
